Lantus Solostar

Insulin glargine, the active ingredient in Lantus Solostar, is a long‑acting insulin analog presented as a 100 U/mL injectable solution (pre‑filled pen) for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients, providing basal insulin coverage to help maintain stable blood glucose levels.

GNH USA supplies Lantus Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide.

Insulin glargine is a long‑acting basal insulin used to manage blood glucose in diabetes mellitus.

- Type 1 diabetes mellitus: provides basal insulin coverage to maintain fasting glucose levels. - Type 2 diabetes mellitus: complements other antidiabetic agents to achieve basal insulin needs. - Diabetes requiring basal insulin support: offers once‑daily dosing to simplify insulin regimens.

The most frequently reported adverse reactions with insulin glargine are related to its pharmacologic action and injection site.

Common Side Effects: - Hypoglycemia: low blood glucose levels, especially if dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with improved glycaemic control. - Lipodystrophy: localized changes in subcutaneous fat at injection sites.

Serious or Rare Side Effects: - Severe hypoglycemia: potentially life‑threatening low blood glucose requiring assistance. - Allergic reactions: rash, urticaria, or angioedema indicating hypersensitivity. - Anaphylaxis: rare systemic allergic response that can be fatal. - Edema: fluid accumulation leading to swelling, particularly in lower extremities.

When using insulin glargine, several precautions should be observed to ensure safe and effective therapy.

- Dose adjustment: titrate dose based on frequent blood glucose monitoring. - Hypoglycemia risk: avoid administration if patient is already hypoglycaemic. - Renal or hepatic impairment: monitor closely as insulin clearance may be reduced. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Concomitant medications: be aware of drugs that may mask hypoglycemia symptoms. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin glargine may interact with other medicines, altering its glucose‑lowering effect or increasing adverse reactions.

Major Interactions (Avoid): - Sulfonylureas or meglitinides: combined use can cause severe hypoglycemia. - Beta‑blockers: may mask signs of hypoglycemia, complicating detection. - Alcohol: excessive intake can potentiate hypoglycemia.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance insulin’s glucose‑lowering effect. - Thiazide diuretics: can increase blood glucose, requiring dose adjustment. - Corticosteroids: may raise glucose levels, necessitating higher insulin doses. - Oral contraceptives: may affect insulin requirements during hormonal changes.